Author Archives: admin

ONWARDS-1 Trial: Icodec in T2DM

Year: 2023 Title: ONWARDS 1 Subtitle: Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin Type of Trial: Randomized, open-label, treat-to-target phase 3a trial Objective: To investigate the efficacy and long-term safety of once-weekly insulin icodec … Read More

ENRICH Trial: Minimally Invasive Removal of ICH

Year: 2024 Title: ENRICH TRIAL Subtitle: Trial of Early Minimally Invasive Removal of Intracerebral Hemorrhage Type of Trial: A multicenter, randomized, adaptive clinical trial Objective: To compare standard medical management to early (<24 hours) surgical hematoma evacuation using minimally invasive … Read More

NADIM II Trial: Nivolumab in Lung Cancer

Objective: To examine the pathological Complete Response defined as the absence of residual tumor in lung and lymph nodes comparing patients treated with chemo-immunotherapy versus chemotherapy alone. Inclusion Criteria: Exclusion Criteria: Participants: 86 Patients Treatment Groups: Primary Outcome: Secondary Outcomes: … Read More

MAESTRO-NASH Trial: Resmetirom for NASH

Objective: To determine if 80 or 100 mg of Resmetirom compared with placebo resolves NASH and/or reduces fibrosis on liver biopsy and prevents progression to cirrhosis and/or advanced liver disease. Inclusion Criteria: Exclusion Criteria: Participants: 966 Patients Treatment Groups: Primary … Read More

LIBRETTO-531 Trial: Selpercatinib in Medullay Thyroid Cancer

Objective: To determine if the study drug selpercatinib is safer and more effective compared to standard treatment in participants with RET-mutant medullary thyroid cancer (MTC) that cannot be removed by surgery or has spread to other parts of the body. … Read More

LIBRETTO-431 Trial: Selpercatinib in NSCLC

Objective: To determine if the study drug selpercatinib, compared to a standard treatment, is effective and safe in participants with RET fusion-positive non-squamous non-small cell lung cancer (NSCLC) that has spread to other parts of the body. Inclusion Criteria: Participants: … Read More

LIXIPARK Trial: Lixisenatide in Early Parkinson’s Disease

Objective: To evaluate the effect of lixisenatide, versus placebo, administered as add-on therapy with the usual antiparkinsonian treatment, on the progression of motor disability in patients with early Parkinson’s Disease (PD) to assess its potential “disease-modifying” effect. Inclusion Criteria: Exclusion … Read More

KETAMORPH Trial: Ketamine for Trauma

Year: 2024 Title: KETAMORPH Subtitle: Ketamine Compared With Morphine for Out-of-Hospital Analgesia for Patients With Traumatic Pain Type of Trial: A prospective, multicenter, single-blind, noninferiority trial Objective: To assess the noninferiority of intravenous ketamine compared with intravenous morphine sulfate to … Read More

CURRENT-OASIS 7: Double Dose Clopidogrel or ASA in ACS

Year: 2010 Title: CURRENT-OASIS 7 Subtitle: Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing PCI for ACS Type of Trial: Double-blind, Randomized Factorial Trial Objective: To evaluate whether a higher dosage of clopidogrel with aspirin (two … Read More

FAST-TAVI II: Reducing LOS after TAVI

Year: 2024 Title: FAST-TAVI II Subtitle: Reducing length of stay after transfemoral transcatheter aortic valve implantation Type of Trial: A prospective, cluster, randomized, controlled trial Objective: To evaluate the efficacy and safety of an intervention (a training program) aimed to … Read More